Condition
Atypical Meningioma
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Unknown2
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT04541082Phase 1Recruiting
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
NCT02847559Phase 2Recruiting
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT03016091Phase 2TerminatedPrimary
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
NCT02973256UnknownPrimary
Oncological Care for Patients With Meningioma
NCT04761653UnknownPrimary
Study of the Inflammatory Microenvironment in Atypical Meningiomas
Showing all 5 trials